Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Modakafusp alfa combination therapy in multiple myeloma
NCT05556616Phase 1Terminated
- Sponsor
- Teva Pharmaceutical Industries Ltd.
- Start
- Jan 2023
- Primary completion
- Jun 2024
- Modality
- Antibody Fragments, Immunomodulatory ADCs, Cytokines & Interferons
- Countries
- 4
01
Overview
Phase 1, open-label trial of modakafusp alfa in multiple myeloma (MM) (7 arms), sponsored by Teva Pharmaceutical Industries Ltd. Primary endpoints: Dose-limiting Toxicities and Treatment Emergent Adverse Events up to 16.7 months. Started Jan 2023; status: terminated.
02
Drugs
modakafusp alfa
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT05556616.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05556616.